-
Mashup Score: 0
Compared with patients with CIDP who received placebo, those who received efgartigimod PH20 showed a decreased risk for clinical deterioration.
Source: www.neurologyadvisor.comCategories: General Medicine News, NeurologyTweet
Compared with patients with CIDP who received placebo, those who received efgartigimod PH20 showed a decreased risk for clinical deterioration.
#AAN2024: Compared with patients with #CIDP who received placebo, those who received #efgartigimod PH20 showed a decreased risk for clinical deterioration. ➡️https://t.co/YbNl9CgkO8 @aanmember #NeuroTwitter